340B Drug Pricing Program

AscellaHealth and ShareSource Partner to Present 2021 Webinar: Driving a Successful Specialty Pharmacy Strategy for Providers, Hospitals and Health-Related Institutions

Retrieved on:

Thursday, February 18, 2021

General Health, Other Health, Hospitals, Health, Pharmaceutical, Health sciences, Health, Pharmaceuticals policy, Specialty drugs, Healthcare reform in the United States, Pharmacy benefit management, Pharmacy, Specialty pharmacy, Prescription drug, Medicare, SCRIPT, 340B Drug Pricing Program

Through this relationship, hospital systems are able to navigate the unique challenges of specialty pharmacy and expand their specialty pharmacy footprint.

Key Points:

Through this relationship, hospital systems are able to navigate the unique challenges of specialty pharmacy and expand their specialty pharmacy footprint.
A second webinar on specialty pharmacy for 340B hospitals is scheduled for late summer 2021.
AscellaHealth , a national specialty pharmacy benefit manager (SPBMTM), serving commercial, Medicare and Medicaid segments, offers high quality prescription drug benefit management services.
Complemented by other customizable services, such as carved-out specialty pharmacy services and cost-savings programs, AscellaHealth provides a unique, proprietary service portfolio.

Verity Solutions #1 for 340B Management Systems for Fourth Year in a Row

Retrieved on:

Friday, February 5, 2021

Health Resources and Services Administration, Drug pricing, 340B Drug Pricing Program

KIRKLAND, Wash., Feb. 4, 2021 /PRNewswire/ --Verity Solutions has been recognized as Best in KLAS for 340B Management Systems (3+ Covered Entities) in the Best in KLAS: Software & Services report , released on February 2, 2021.

Key Points:

KIRKLAND, Wash., Feb. 4, 2021 /PRNewswire/ --Verity Solutions has been recognized as Best in KLAS for 340B Management Systems (3+ Covered Entities) in the Best in KLAS: Software & Services report , released on February 2, 2021.
This is the fourth consecutive win for Verity Solutions, the only organization in the 340B Management Systems category to accomplish this.
Verity 340B is one of the most comprehensive 340B program management solutions available for covered entities allowing hospitals, IDNs, Community Health Centers, FQHCs, and their retail pharmacies to quickly and easily scale their 340B program.
Hundreds of health systems rely on Verity Solutions to simplify their 340B program administration, optimize federal pricing benefits, and leverage their expert team.

Hospital Practices Increase Costs of Medicines for Patients & Employers, New Report Shows

Retrieved on:

Thursday, February 4, 2021

Drug pricing, Health Resources and Services Administration, 340B Drug Pricing Program, Pharmaceuticals policy, Prescription drug prices in the United States

Specifically, the report documents how hospital markups, consolidation, the site of care in which a medicine is administered and the 340B program impact the cost of medicines and health care spending.

Key Points:

Specifically, the report documents how hospital markups, consolidation, the site of care in which a medicine is administered and the 340B program impact the cost of medicines and health care spending.
"Many actors including hospitals, insurers and other middlemen influence what patients pay out of pocket for prescription medicines.
Key findings from the report include:
Hospitals often inflate the cost of medicines administered to commercially insured patients in outpatient settings.
Hospital consolidation often forces patients to shift their care to less efficient, more costly settings without any corresponding increase in the quality of care .

Sentry Data Systems Ranked #1 in 340B Pharmacy Management Systems from Black Book Research

Retrieved on:

Tuesday, January 26, 2021

Fictional characters, Marvel Comics characters, Articles, Oceanography, Sentry, Pharmacist, Pharmacy management system, Pharmacy, Procurement, 340B Drug Pricing Program

DEERFIELD BEACH, Fla., Jan. 26, 2021 /PRNewswire/ -- Sentry Data Systems, Inc., the nation's leader in pharmacy procurement, compliance and utilization management, today announced that the company has achieved the top ranking in the annual 340B Pharmacy Management Systems Black Book Research report, including the highest scores for user experience and outcomes.

Key Points:

DEERFIELD BEACH, Fla., Jan. 26, 2021 /PRNewswire/ -- Sentry Data Systems, Inc., the nation's leader in pharmacy procurement, compliance and utilization management, today announced that the company has achieved the top ranking in the annual 340B Pharmacy Management Systems Black Book Research report, including the highest scores for user experience and outcomes.
Unlike other subjective industry ratings, Black Book Research's report is based on a quantitative study including 1,169 hospital executive participants (primarily pharmacy leaders) evaluating 31 340B product and service vendors from July to December 2020.
"We're pleased to accept this top honor from Black Book Research, particularly given that the organization avoids conflicts of interest by accepting no financial reimbursement from participating vendors prior to publishing their objective results," said Travis Leonardi, RPh, CEO of Sentry Data Systems.
Sentry received top honors in many of Black Book's 18 Key Performance Indicators including:

Nevada Shelves Program Cuts in Victory for HIV Patients: Federal 340B Changes Forestalled

Retrieved on:

Thursday, January 14, 2021

AIDS, White House, Federal Government, Public policy, Government, Health, State, Local, Infectious diseases, Health Resources and Services Administration, 340B Drug Pricing Program, Drug pricing

This delay will allow DPBH additional time to review the impact of community partners using the federal 340B program and the program income received directly to them and the impact of rebate revenue received at NMAP.

Key Points:

This delay will allow DPBH additional time to review the impact of community partners using the federal 340B program and the program income received directly to them and the impact of rebate revenue received at NMAP.
After Nevada health officials first announced the plan, many community partners and nonprofit HIV providers decried the states action, warning it could have a profound and negative impact on patient care.
The 340B program, which costs taxpayers nothing, allows Ryan White HIV Clinics and providers to acquire HIV drugs at a steep discount, using the savings from those discounts to pay for HIV services not covered by their Ryan White grants.
Some of the advocates and HIV providers also ran an advocacy ad ( 340B ad ) targeting Nevada health officials and legislators urging state officials to not to interfere with the states successful 340B program.

AHF to Protest Amgen Over Unlawful Drug Restrictions

Retrieved on:

Monday, December 21, 2020

They depend on the savings from the 340B program to keep open to stretch existing federally funded health care programs.

Key Points:

They depend on the savings from the 340B program to keep open to stretch existing federally funded health care programs.
The rapacious greed of Amgen is limitless, said John Hassell, national director of advocacy for AHF.
AHF calls on the U.S. Department of Health and Human Services ( HHS ) to do its job and stop this callous drug industry attack on the U.S. healthcare safety net.
Its a social justice imperative for the new administration to protect the 340B Drug Discount Program.

AHF to HRSA: Reject Kalderos’ Plan to Hurt 340B Drug Discount Program

Retrieved on:

Monday, December 21, 2020

Other Government, Infectious diseases, Congressional News, Views, Public policy, Government, AIDS, Health, Pharmaceutical, Public policy, Other Policy Issues, Health Resources and Services Administration, Pricing, Rebate, Sales promotion, Drug pricing, 340B Drug Pricing Program

The Kalderos plan would convert the 340B Drug Price Program from a discount to a rebate program and would set Kalderos up as the arbiter of who will get the rebate and when, putting the fox in charge of the henhouse, said Tom Myers, AHF chief of public affairs and general counsel.

Key Points:

The Kalderos plan would convert the 340B Drug Price Program from a discount to a rebate program and would set Kalderos up as the arbiter of who will get the rebate and when, putting the fox in charge of the henhouse, said Tom Myers, AHF chief of public affairs and general counsel.
Under the 340B statute, drug manufacturers are required to sell drugs to safety net providers at or below the discount price.
Congress intentionally expanded the 340B program with the full knowledge and explicit approval of the drug industry.
AHF urges the U.S. Health Resources and Services Administration which runs the 340B to assert its authority as enforcer of the 340B program and reject the Kalderos steal, concluded Myers.

Kalderos upgrades 340B Pay platform, giving covered entities more options

Retrieved on:

Tuesday, December 15, 2020

Health Resources and Services Administration, Drug pricing, 340B Drug Pricing Program, Healthcare reform in the United States, Rebate, Medicaid

CHICAGO, Dec. 15, 2020 /PRNewswire/ -- Drug Discount Management company Kalderos today announced a significant upgrade to its 340B Pay solution that gives covered entities more choice in how they realize the benefits of the 340B program.

Key Points:

CHICAGO, Dec. 15, 2020 /PRNewswire/ -- Drug Discount Management company Kalderos today announced a significant upgrade to its 340B Pay solution that gives covered entities more choice in how they realize the benefits of the 340B program.
The solution enables manufacturers, covered entities and Medicaid agencies to work together to effectuate 340B discounts compliantly and efficiently.
340B Pay, and its tools, Request and Verify, allow providers of any size to request 340B rebates and manufacturers to verify and pay them through a third party payment partner.
With 340B rebate funds from contract pharmacy dispenses flowing directly to covered entities, covered entities will benefit from greater control over program savings, enabling them to better serve patients.

28 State AGs Demand HHS Sec. Azar Enforce Laws on 340B Drug Pricing

Retrieved on:

Tuesday, December 15, 2020

AIDS Healthcare Foundation ( AHF ) praised 28 U.S. state attorneys general who have drawn a line in the sand to protect an essential part of the healthcare safety net: the 340B Drug Pricing Program against the limitless greed of the drug industry.

Key Points:

AIDS Healthcare Foundation ( AHF ) praised 28 U.S. state attorneys general who have drawn a line in the sand to protect an essential part of the healthcare safety net: the 340B Drug Pricing Program against the limitless greed of the drug industry.
In their December 14 letter , the bipartisan group of elected attorneys general demand that U.S. Health and Human Services ( HHS ) Secretary Alex Azar take immediate steps to enforce the law to address drug companies unlawful refusal to provide critical drug discounts to covered entities such as community health centers under the 340B Drug Pricing Program.
View the full release here: https://www.businesswire.com/news/home/20201214005885/en/
Letter to HHS Secretary Alex Azar from 28 state AGs demanding that he enforce the law on 340B drug pricing as required by section 340B of the U.S. Health Services Act.
AHF has repeatedly criticized these nine drug companies whose actions the AGs are calling unlawful.

AHF Blasts Amgen Over Drug Restrictions; Asks Biden Administration to Sanction It and Others

Retrieved on:

Thursday, December 10, 2020

AIDS, White House, Federal Government, Public policy, Government, Healthcare reform, Health, Pharmaceutical, Health Resources and Services Administration, Pharmaceutical industry, Pharmacology, Pharmacy, Drug pricing, 340B Drug Pricing Program

The U.S. government already gives special favors to drug companies to produce expensive orphaned drugs for rare diseases that would otherwise be unaffordable.

Key Points:

The U.S. government already gives special favors to drug companies to produce expensive orphaned drugs for rare diseases that would otherwise be unaffordable.
They depend on the savings from the 340B program to keep open to stretch existing federally funded health care programs.
Its a social justice imperative for the new administration to protect the 340B Drug Discount Program.
To learn more about AHF, please visit our website: www.aidshealth.org , find us on Facebook: www.facebook.com/aidshealth and follow us @aidshealthcare .